CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6300
+0.1300 (+8.67%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.5000
Open1.5000
Bid1.5600 x 3100
Ask1.6300 x 4000
Day's Range1.4975 - 1.6400
52 Week Range1.2900 - 14.0000
Volume1,346,869
Avg. Volume2,419,588
Market Cap111.983M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.4350
Earnings DateNov 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.31
  • Steven Cohen Renews His Interest in Verastem
    GuruFocus.com

    Steven Cohen Renews His Interest in Verastem

    Guru invests in restructuring cancer drug developer Continue reading...

  • GlobeNewswire

    CymaBay Publishes Shareholder Letter

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the publication of a Letter to Shareholders. In this Letter to Shareholders, CymaBay updates its shareholders on ongoing activities at CymaBay, including in regard to its close out of its seladelpar clinical studies and efforts to maximize shareholder value. CymaBay also provides an estimate of its 2019 year-end cash and an estimate of its cash burn in the first half of 2020.

  • Thomson Reuters StreetEvents

    Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Cymabay Therapeutics Inc Earnings Call

  • CymaBay Therapeutics Enters Oversold Territory
    Zacks

    CymaBay Therapeutics Enters Oversold Territory

    CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • These Falling Knives May Be Worth Catching
    GuruFocus.com

    These Falling Knives May Be Worth Catching

    They have a low financial burden, which reduces the risk of default Continue reading...

  • Gilead (GILD) Announces Top-Line Results From NASH Study
    Zacks

    Gilead (GILD) Announces Top-Line Results From NASH Study

    Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.

  • Genfit Hopes to Buck the Odds With NASH Drug
    GuruFocus.com

    Genfit Hopes to Buck the Odds With NASH Drug

    French biopharmaceutical company hopes to become first to get approval of treatment for liver disorder that affects up to 30 million Americans Continue reading...

  • Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)?
    Simply Wall St.

    Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ?

    How do we determine whether CymaBay Therapeutics Inc (NASDAQ:CBAY) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
    Zacks

    The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

    The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

  • NASH Scorecard Year to Date: The Winners and the Losers
    Zacks

    NASH Scorecard Year to Date: The Winners and the Losers

    NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

  • Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
    Zacks

    Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

    Key highlights of the past week include regulatory and pipeline updates.

  • Company News For Nov 26, 2019
    Zacks

    Company News For Nov 26, 2019

    Companies In The News Are:

  • Intercept's (ICPT) NDA for NASH Drug Gets Priority Review
    Zacks

    Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

    Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

  • Benzinga

    The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test
    Investor's Business Daily

    This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test

    Intercept Pharmaceuticals stock rocketed Monday after FDA regulators granted its NASH treatment priority review and after competing biotech company CymaBay scrapped its rival drug.

  • Reuters

    UPDATE 2-CymaBay Therapeutics scraps two studies of liver drug; shares plunge

    CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%. The drug developer said it had observed "atypical" findings from the first set of liver biopsies, including autoimmune hepatitis, in one mid-stage trial that was testing the drug in patients with a fatty liver disease known as non-alcoholic steatohepatitis (NASH). The drug developer said it will terminate the NASH study as well as another mid-stage study testing the drug in patients with primary sclerosing cholangitis, while it would also halt a late-stage study of the drug in primary biliary cholangitis (PBC), an autoimmune liver disorder.

  • MarketWatch

    CymaBay shares fall 77% on halted trial

    Shares of CymaBay Therapeutics Inc. are down 77% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar. CymaBay had been testing the therapy as a treatment for non-alcoholic steatohepatitis (NASH) and in patients with primary sclerosing cholangitis and primary biliary cholangitis, both liver diseases. "We are very disappointed in having to halt the development of seladelpar at this time but patient safety and care is paramount," CEO Sujal Shah said in a news release. CymaBay stock has fallen 29% year-to-date. The S&P 500 is up 24%.

  • GlobeNewswire

    CymaBay Therapeutics Halts Clinical Development of Seladelpar

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that the company was terminating its Phase 2b study of seladelpar in subjects with non-alcoholic steatohepatitis (NASH) and its recently initiated Phase 2 study of seladelpar in subjects with primary sclerosing cholangitis (PSC). In addition, the company is putting on hold all studies of seladelpar in subjects with primary biliary cholangitis (PBC). The decision to halt development of seladelpar was based on initial histological findings observed in the Phase 2b study of seladelpar in NASH.

  • 3 “Strong Buy” Biotech Stocks to Watch After Stifel Healthcare Conference
    TipRanks

    3 “Strong Buy” Biotech Stocks to Watch After Stifel Healthcare Conference

    Are you prone to sudden surges of joy, abruptly followed by sinking bouts of misery? Do you react disproportionately to good or bad news? Well then, you might just be a biotech stock.Known for extreme volatility, biotech stocks can be great news for the risk tolerant investor, but of course, the flipside means they can be bad news, too. So, in this tricky sector, it is hard to know how to choose the right stock to invest in.At Stifel’s recent Healthcare Conference in New York, the investment banking firm took a deep look at some of the biotechs' latest developments. Following the conference’s close, we decided to get the magnifying glass out, and with the help of TipRanks’ Stock Screener home in on the biotech stocks Stifel singled out, but in particular, ones with a Strong Buy consensus rating. Let's dive in.CymaBay Therapeutics (CBAY)First up is CymaBay Therapeutics, a company on a mission to improve the lives of patients with liver and other chronic diseases. The biopharma focuses on developing innovative therapies for patients with rare conditions in which the lack of a market doesn’t cater to their medical needs. These are known as orphan diseases.The company’s main drug is Seladelpar, currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).As if to prove our introduction regarding biotechs’ volatility, CymaBay lost over 50% in one day in June, following mixed results from the company’s Phase 2b study in NASH, which exhibited minimal reductions in liver fat compared to placebo. Since then the stock has yet to regain a foothold on the market ladder.Stifel’s analyst Derek Archila sat down with CymaBay management, and got the lowdown from the team regarding the Seladelpar trials. The analyst noted, “On the commercial front, management highlighted the potential of seladelpar as part of a combo therapy, with already approved therapies such as the GLP-1R agonists of SGLT2s, given NASH is a multi-factorial disease. We agree with this and see combination therapies playing a key role in treating NASH patients.” Archila further added, “Although NASH is important to the CBAY story, management indicated they view the company as an orphan disease company given seldelpar development is furthest along in PBC, with the Phase 3 ENHANCE study recently completing enrollment. We believe seladelpar has demonstrated sufficient proof-of-concept in this indication.” CymaBay remains on track to report topline data from ENHANCE 52-week study in early 2021.Reassured by the meeting, Archila reiterated his Buy rating on CBAY along with a price target of $14. With CBAY currently trading at $5.61, this indicates substantial upside potential of 150%. (To watch Archila’s track record, click here)It seems like the Street is with Archila on this one. With 3 Buys and 1 Hold the biotech stock has Strong Buy pasted across its label. Importantly, CBAY has an average price target of $14.25, an even slightly more bullish outcome than Archila’s target. (See CymaBay stock analysis on TipRanks)Heron Therapeutics (HRTX)Next up is Heron Therapeutics, a biotech developing treatments for patients suffering from cancer or postoperative pain.The company experienced what we shall call a “biotech classic” in May, when it lost roughly 30% of its value following an FDA rejection of its experimental post-operative pain medication, HTX-011. The rejection centered around the lack of Chemistry, Manufacturing and Controls (CMC) data and was not based on clinical or safety issues.Things are looking up though. In October the FDA accepted Heron’s NDA resubmission for HTX-011 with a PDUFA date set for March 26, 2020. The company is expecting approval and is gearing up to launch HTX-011 shortly thereafter.Stifel’s Derek Archila recently met up with Heron’s CEO Barry Quart, who told Archila: "2020 will be a big year for the company."The analyst noted, “The key point the CEO emphasized is that HRTX's chemo-induced nausea and vomiting (CINV) franchise (Cinvanti and Sustol) is an excellent platform to leverage for the launch of HTX-011 because the target hospitals are very similar. The strategy and tailwinds behind the launch of Cinvanti, such as improved product profile and favorable reimbursement, have produced 42% market share in a market that was 100% controlled by MRK's Emend. Similarly, management believes HTX-011 has an improved profile compared to both generic bupivacaine and PCRX's Exparel both in terms of efficacy and usability.”To this end, Archila reiterated a Buy rating on HRTX stock alongside a $36 price target, indicating an increase of 45% from the recent share price.There’s further good news for HRTX, as currently TipRanks gives Heron a Strong Buy consensus rating. This breaks down into a unanimous 7 "buy" ratings. With an average stock-price forecast of $45.86, the street is in even more of a bullish mood than Archila, providing ample upside of 86% from current levels. (See Heron stock analysis on TipRanks)Argenx (ARGX)Completing our trio of biotechs is the Netherlands’ based Argenx. In a similar vein to both our previous choices, the biopharma focuses on patients with unmet medical needs. Its modus operandi is the development of antibody-based therapies for the treatment of severe auto-immune diseases and cancer.Argenx’s lead drug candidate is efgartigimod, a treatment for patients with severe autoimmune disorders associated with high levels of pathogenic immunoglobulin G, or IgG. Argenx has high hopes for the drug and believes it can have a wide therapeutic impact. It is currently being investigated in MG (myasthenia gravis - a neuro muscular disease), immune thrombocytopenia (a shortage of blood cell fragments needed for normal blood clotting) and skin blistering diseases.At Stifel’s recent Healthcare Conference, Derek Archila sat down with Argenx CEO Tim Van Hauwermeiren for a fire side chat regarding efgartigimod’s progress. The analyst noted, "The first indication it will likely be approved for is MG, for which ARGX expects Phase 3 ADAPT data in 2H20. Management has guided to a potential launch in 2021 for MG. Briefly on the launch, management expects efgartigimod to be used early in the treatment algorithm, after corticosteroids. Efgartigimod will be launched as an IV infusion but has plans to bring a SC form to market in MG.”As a result, Archila reiterated a Buy rating on ARGX along with a price target of $154, implying about 10% upside for the stock.All in all, the rest of the Street has an optimistic view of ARGX. The stock’s Strong Buy status comes from the 7 "buy" and 2 "hold" ratings issued over the previous three months. The upside potential lands at 11%, slightly above Archila's forecast. (See Argenx stock analysis on TipRanks)

  • GlobeNewswire

    CymaBay Therapeutics to Present at Upcoming Investor Conferences

    NEWARK, Calif., Nov. 14, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative.

  • GlobeNewswire

    CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEWARK, Calif., Nov. 05, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.

  • GlobeNewswire

    CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with a high unmet medical need, today announced achievement of the targeted 240 patient enrollment goal for ENHANCE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC). With more than 240 patients enrolled, ENHANCE is CymaBay’s lead regulatory registration study evaluating the safety and efficacy of its investigational drug, seladelpar, for patients already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol), but have not achieved the recommended treatment goal or cannot tolerate UDCA.

  • Is CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) CEO Salary Justified?
    Simply Wall St.

    Is CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) CEO Salary Justified?

    In 2017 Sujal Shah was appointed CEO of CymaBay Therapeutics, Inc. (NASDAQ:CBAY). This analysis aims first to contrast...

  • GlobeNewswire

    CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5

    NEWARK, Calif., Oct. 28, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.